Physician

Kaleem Ahmad, M.D.

According to 2025 Medicare claims, Kaleem Ahmad, M.D. (NPI: 1629065982) practices hematology/oncology in the Atlantic City-Hammonton, NJ market, with the plurality of this provider's patient population coming from Cape May, NJ. This provider's primary affiliated billing organization is REGIONAL CANCER CARE ASSOCIATES LLC (NPI: 1801850243; TIN: 223141761) and primary practice location at 08210-2122.

Ahmad's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 729 traditional Medicare patients, billed 171,471 HCPCS/CPT codes, and received $1,701,204 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 758 prescription claims across 181 beneficiaries totaling $2,160,303 in drug costs, led by Jakafi (Ruxolitinib Phosphate). 2023 DME data shows 29 claims. Open Payments data shows 121 records totaling $2,221. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $1,201,350 to $2,160,303. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $3,326 to $382.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	787	184,442	$1,382,511
2016	865	219,930	$2,058,115
2017	827	197,416	$2,013,412
2018	737	180,742	$1,955,352
2019	736	163,149	$1,738,164
2020	727	216,613	$2,263,518
2021	691	237,829	$2,285,826
2022	634	169,947	$1,692,833
2023	693	156,188	$1,862,599
2024	729	171,471	$1,701,204

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	175	980	$1,201,350
2016	185	1,030	$1,659,505
2017	180	920	$1,611,926
2018	168	1,024	$1,724,756
2019	177	1,045	$2,380,456
2020	205	925	$2,150,149
2021	193	924	$2,559,071
2022	194	945	$2,898,226
2023	183	849	$2,324,401
2024	181	758	$2,160,303

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	23	$1,909
2016	N/R	78	$30,823
2017	N/R	38	$9,461
2018	N/R	71	$6,698
2019	N/R	97	$10,529
2020	N/R	69	$4,846
2021	N/R	54	$4,021
2022	N/R	27	$841
2023	N/R	29	$2,046
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	370	737	$100
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	259	385	$69
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	180	358	$13
36415	Insertion of needle into vein for collection of blood sample	569	1,686	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	588	1,829	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	26	780	$454,482
Promacta	Eltrombopag Olamine	28	840	$367,088
Pomalyst	Pomalidomide	13	348	$278,788
Revlimid	Lenalidomide	14	392	$224,305
Brukinsa	Zanubrutinib	11	330	$161,092

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	121	$2,221	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Kaleem Ahmad, M.D.?

Tedicare shows public-source Medicare data for Kaleem Ahmad, M.D. (NPI 1629065982), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kaleem Ahmad, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Kaleem Ahmad, M.D.?

Kaleem Ahmad, M.D. is linked to REGIONAL CANCER CARE ASSOCIATES LLC (billing NPI 1801850243) in the available physician profile data.

Does Kaleem Ahmad, M.D. have Open Payments data?

Kaleem Ahmad, M.D. has 121 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.